Boston Advisors LLC raised its stake in Amedisys Inc. (NASDAQ:AMED) by 52.5% during the second quarter, Holdings Channel reports. The institutional investor owned 36,687 shares of the company’s stock after buying an additional 12,624 shares during the period. Boston Advisors LLC’s holdings in Amedisys were worth $1,852,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Nuveen Asset Management LLC increased its stake in shares of Amedisys by 46.2% in the first quarter. Nuveen Asset Management LLC now owns 45,382 shares of the company’s stock valued at $2,193,000 after buying an additional 14,334 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Amedisys by 81.1% in the first quarter. Renaissance Technologies LLC now owns 630,901 shares of the company’s stock valued at $30,498,000 after buying an additional 282,600 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Amedisys by 53.8% in the first quarter. Goldman Sachs Group Inc. now owns 61,584 shares of the company’s stock valued at $2,977,000 after buying an additional 21,535 shares in the last quarter. State Street Corp increased its stake in shares of Amedisys by 6.3% in the first quarter. State Street Corp now owns 686,983 shares of the company’s stock valued at $33,211,000 after buying an additional 40,819 shares in the last quarter. Finally, M&T Bank Corp acquired a new stake in shares of Amedisys during the first quarter valued at $367,000. Institutional investors and hedge funds own 91.45% of the company’s stock.
Shares of Amedisys Inc. (NASDAQ:AMED) traded up 0.27% during midday trading on Friday, hitting $47.44. The stock had a trading volume of 352,605 shares. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of 41.50 and a beta of 1.05. Amedisys Inc. has a 1-year low of $31.16 and a 1-year high of $55.16. The firm’s 50-day moving average price is $48.27 and its 200-day moving average price is $49.66.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported $0.42 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.42. The company earned $360 million during the quarter, compared to analysts’ expectations of $353.07 million. Amedisys had a return on equity of 12.17% and a net margin of 2.78%. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.43 earnings per share. Analysts forecast that Amedisys Inc. will post $1.69 earnings per share for the current year.
Several analysts recently weighed in on the company. Mizuho downgraded Amedisys from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $57.00 to $55.00 in a research report on Wednesday, August 3rd. Zacks Investment Research downgraded Amedisys from a “hold” rating to a “sell” rating in a research report on Monday, July 11th. Stephens initiated coverage on Amedisys in a report on Thursday, June 16th. They issued an “equal weight” rating and a $55.00 target price for the company. Jefferies Group reaffirmed a “buy” rating on shares of Amedisys in a report on Tuesday, September 6th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Amedisys in a report on Sunday, September 11th. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $51.75.
Amedisys Company Profile
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc. (NASDAQ:AMED).
Receive News & Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.